SOHO Announces Poster Award Winners at Eleventh Annual Meeting

HOUSTON — Of the many posters that were displayed on the first evening of the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO), eight posters received awards from the Society during a ceremony held Wednesday evening.

In first place was the poster titled “TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)” which was presented by Loretta Nastoupil, MD, of the University of Texas MD Anderson Cancer Center, and colleagues.

The second-place poster award went to “Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT),” which was presented by Natalie Callander, MD, of University of Wisconsin Carbone Cancer Center, and colleagues.

The third-place poster award went to the poster titled “First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia,” which was presented by Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, and colleagues.

The following posters received honorable distinctions:

• “Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III.” Presented by Faye Feller, MD, of Geron Corporation, and colleagues.
• “Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial.” Presented by Richard Schlenk, MD, of the Heidelberg University Hospital and German Cancer Research Center, and colleagues.
• “Longer follow-up reaffirms subcutaneous epcoritamab induces deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial.” Presented by Yasmin Karimi, MD, of the University of Michigan Comprehensive Cancer Center, and colleagues.
• “Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML.” Presented by Harry Erba MD, PhD, of the Duke Cancer Institute, and colleagues.
• “Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion.” Presented by Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, and colleagues.